Zobrazeno 1 - 10
of 64
pro vyhledávání: '"John L. Stock"'
Autor:
Stuart L. Silverman, L.A. Russo, Mark Lakshmanan, Russel Burge, Christopher Recknor, Bruce H. Mitlak, John L. Stock, Jahangir Alam, Fergus McKiernan, Kenneth G. Saag, D. N. Masica, Peyman Hadji, J.R. Zanchetta, John H. Krege
Publikováno v:
Osteoporosis International. 23:2141-2150
The effect of teriparatide and risedronate on back pain was tested, and there was no difference in the proportion of patients experiencing a reduction in back pain between groups after 6 or 18 months. Patients receiving teriparatide had greater incre
Autor:
Santiago Palacios, Sherie A. Dowsett, Jahangir Alam, Jose R. Zanchetta, David L. Kendler, John L. Stock, David A. Cox
Publikováno v:
Osteoporosis International. 23:1091-1101
Arzoxifene increased bone mineral density and decreased bone turnover to a significantly greater extent than raloxifene. The hot flush incidence was lower with arzoxifene than raloxifene. To assess the effect of arzoxifene versus raloxifene on change
Autor:
Kristine E. Ensrud, Jane A. Cauley, John L. Stock, Lori Mosca, Elizabeth Barrett-Connor, Kay-Tee Khaw, Deborah Grady, D Agnusdei, Qingwen Zhao
Publikováno v:
Journal of Bone and Mineral Research. 23:112-120
Using data from a randomized placebo-controlled trial of 10,101 postmenopausal women not selected on the basis of osteoporosis, we examined whether the effect of raloxifene treatment on fractures was consistent across categories of fracture risk. Tre
Publikováno v:
Journal of Clinical Densitometry. 8:273-277
The ISCD recommends that bone mineral density (BMD) be monitored in patients undergoing antiresorptive therapy to identify patients with a significant BMD loss. This analysis compares the proportions of postmenopausal women treated with raloxifene 60
Autor:
Stefan Goemaere, Steven R. Cummings, John L. Stock, Adolfo Diez-Perez, Yongming Qu, Richard Eastell, Jose R. Zanchetta, Steven T. Harris, Jingli Song, Suresh Siddhanti, Ethel S. Siris, Pandurang M. Kulkarni, Mayme Wong
Publikováno v:
Journal of Bone and Mineral Research. 20:1514-1524
In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE had limitations for assessing fracture risk. In a subset of 386 women, 7
Autor:
John L. Stock, Pierre D. Delmas, Mayme Wong, Leo Plouffe, Pandurang M. Kulkarni, Stuart L. Silverman
Publikováno v:
Journal of the American Geriatrics Society. 52:1543-1548
Objectives: To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis. Design: A prospective, observational study of the placebo group in the double-blind, randomized Multipl
Autor:
John L. Stock, Angelina V. Ciaccia, Edward G. Lufkin, Suresh Siddhanti, Pandurang M. Kulkarni, Somnath Sarkar, Leo Plouffe
Publikováno v:
Current Medical Research and Opinion. 20:351-357
Standard pharmacological antiresorptive therapy for the prevention and/or treatment of postmenopausal osteoporosis now consists of four categories of drugs: estrogens, a selective estrogen receptor modulator (SERM), bisphosponates, and calcitonin. Al
Publikováno v:
Endocrine Reviews. 23:16-37
Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective
Autor:
Kausik Ray, John L. Stock, Maria Veronica Mericq, Jeffrey Baron, Edna E. Mancilla, Rosalind S. Brown, James A. Coderre, Francesco De Luca
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 84:3036-3040
Familial hypoparathyroidism is an unusual and genetically heterogeneous group of disorders that may be isolated or may be associated with congenital or acquired abnormalities in other organs or glands. We have evaluated a family with a novel syndrome
Autor:
M. L. Brandi, Frank P. Alford, T. T. Tan, Bin Tean Teh, Marilyn K. Walters, Britt Skogseid, L. Tranebjærg, Joseph J. Shepherd, Siew Pheng Chan, A. Khir, Fung Ki Wong, Magnus Nordenskjöld, Albert Beckers, Catherine M. Phelan, A. Zaini, Fabienne Parente, Soili Kytölä, Kerstin Sandelin, Matthew S. Edwards, L. Bergman, B. A. K. Khalid, Shideh Khodaei, D Hurley, Pasi I. Salmela, John L. Stock, Catharina Larsson, Christine Stewart, Nicholas K. Hayward, J. Leisti, M. Warth, John Cardinal, Norman W. Thompson, Filip Farnebo, Sean M. Grimmond, M. Epstein, Günther Weber, R. Jorde, Ginters Silins, David Cameron, J. Menon, Kjell Öberg
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 83:2621-2626
Multiple endocrine neoplasia type 1 (MEN 1) is an autosomal dominant disease characterized by neoplasia of the parathyroid glands, the endocrine pancreas, and the anterior pituitary gland. In addition, families with isolated endocrine neoplasia, nota